| Type | Title | Date Released | |
|---|---|---|---|
8-K | Cullinan Therapeutics Announces Positive Clinical Data for Velinotamig in Systemic Lupus Erythematosus at ACR Convergence 2026 New | ||
4 | Michaelson Jennifer (Reporting) | ||
144 | Form 144 | ||
8-K | Cullinan Therapeutics Announces Presentations for CLN-049 and Velinotamig at the 68th ASH Annual Meeting | ||
8-K | New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC Under FDA Real-Time Oncology Re | ||
8-K | Cullinan Therapeutics Highlights Fourth Quarter 2026 Pipeline Milestones Across Immunology and Oncology T Cell Engager Portfolio | ||
8-K | Zipalertinib Plus Chemotherapy Demonstrates Positive Progression-Free Survival in REZILIENT3 Phase 3 Trial for First-Line NSCLC | ||
4 | Michaelson Jennifer (Reporting) | ||
144 | Form 144 | ||
4 | Michaelson Jennifer (Reporting) | ||
SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND L P (Filed by) | ||
SCHEDULE 13G | PRICE T ROWE ASSOCIATES INC /MD/ (Filed by) |
